AssetMark Inc
ARQT icon

AssetMark Inc’s Arcutis Biotherapeutics ARQT Stock Holding History

AssetMark Inc’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$53.3K Buy
2,017
+5
+0.2% +$131 ﹤0.01% 1860
2026
Q2 		$52.8K Buy
2,012
+495
+33% +$11.5K ﹤0.01% 1816
2026
Q1 		$35.7K Hold
1,517
– – ﹤0.01% 1859
2025
Q4 		$44.1K Sell
1,517
-343
-18% -$8.78K ﹤0.01% 1761
2025
Q3 		$35.1K Hold
1,860
– – ﹤0.01% 1761
2025
Q2 		$26.1K Hold
1,860
– – ﹤0.01% 1740
2025
Q1 		$29.1K Hold
1,860
– – ﹤0.01% 1599
2024
Q4 		$25.9K Hold
1,860
– – ﹤0.01% 1594
2024
Q3 		$17.3K Hold
1,860
– – ﹤0.01% 1526
2024
Q2 		$17.3K Hold
1,860
– – ﹤0.01% 1409
2024
Q1 		$18.4K Hold
1,860
– – ﹤0.01% 1294
2023
Q4 		$6.01K Hold
1,860
– – ﹤0.01% 1434
2023
Q3 		$9.9K Hold
1,860
– – ﹤0.01% 1335
2023
Q2 		$17.7K Buy
1,860
+255
+16% +$2.83K ﹤0.01% 1227
2023
Q1 		$17.7K Buy
1,605
+250
+18% +$3.62K ﹤0.01% 1205
2022
Q4 		$20.1K Buy
1,355
+440
+48% +$7.69K ﹤0.01% 1203
2022
Q3 		$17K Buy
915
+375
+69% +$8.5K ﹤0.01% 1152
2022
Q2 		$12K Buy
+540
New +$11.1K ﹤0.01% 1197

Other funds holding ARQT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Jay A. Fishman Ltd
Jay A. Fishman Ltd Troy, Michigan $1.24B AUM 21.21% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

AssetMark Inc's ARQT Position: Q3 2026 in Review

AssetMark Inc increased its Arcutis Biotherapeutics (ARQT) stake by 0.25% in Q3 2026, buying an estimated $131 and bringing the position to 2,017 shares worth $53.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

AssetMark Inc first reported a position in ARQT in Q2 2022 and has held it in 18 quarters since. 112 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • AssetMark Inc held 2,017 shares of Arcutis Biotherapeutics worth $53.3K as of Q3 2026.
  • AssetMark Inc bought 5 Arcutis Biotherapeutics shares in Q3 2026, an estimated $131.
  • Arcutis Biotherapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1860 holding.
  • AssetMark Inc first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 18 quarters since.
  • 112 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.